The global breast cancer liquid biopsy market is expected to reach USD 761.73 million by 2025, from USD 145.4 million in 2017 growing at a CAGR of 23.0% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Get Free Sample Copy of this Report@ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-breast-cancer-liquid-biopsy-market
Market Definition: Global Breast Cancer Liquid Biopsy Market
Liquid biopsy is a non-invasive technique which is used to detect molecular biomarkers by using liquid samples. This technology does not need invasive or costly procedures. The liquid biopsy helps in early cancer diagnosis & detection, easy and minimal invasiveness, therapeutic & drug target identifications for cancer treatment and characterization of new lesions. This technique improves the safety and efficiency of cancer therapy for patients by detecting problem at early stage without any invasiveness.
In August 2017, Cynvenio Biosystems, Inc. (Westlake Village, CA), launched its new ClearID HER2 Expression Test. This new test allows doctors to perform real-time monitoring and gets analysis of HER2 levels in their patients without tissue biopsy.
Major Market Drivers and Restraints:
- Rising applications of liquid biopsy.
- Rising geriatric population along with cancer incidences.
- Increasing focuses on R&D in medical field for cancers.
- Clinical utility challenges towards liquid biopsy.
Request for Detailed TOC : https://databridgemarketresearch.com/toc/?dbmr=global-breast-cancer-liquid-biopsy-market
Market Segmentation: Global Breast Cancer Liquid Biopsy Market
The global breast cancer liquid biopsy market is segmented based on product, circulating biomarkers, end user and geographical segments.
Based on product type, the market is segmented into consumables and kits
On the basis of circulating biomarkers, the market is segmented into Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs) and cfRNA.
On the basis of end users, the market is segmented into laboratories, hospitals, physician laboratories, public health laboratories, research institutes, small molecular laboratories and pathology laboratories
Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and Brazil among others.
Key Developments in the Market:
- In August 2017, Cynvenio Biosystems, Inc. (WESTLAKE VILLAGE) launched its second generation PD-L1 expression test. This new blood test offers improved analytic performance as compare to first generation PD-L1 test and has high sensitivity, specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
- In May 2017, Cynvenio Biosystems Inc. (Westlake Village, Calif), released ClearID Total Insight Breast Cancer which is a liquid biopsy monitoring service for patients to treat cancer related problems.
Competitive Analysis: Global Breast Cancer Liquid Biopsy Market
The Global Breast Cancer Liquid Biopsy Market is highly fragmented and the major players have used various strategies such product launches, technology developments, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Continuous Manufacturing market for global, Europe, North America, Asia Pacific and South America.
In August 17, 2017, Cynvenio Biosystems, Inc. (WESTLAKE VILLAGE, CA), launched new breast cancer monitoring study in business with Saint Luke’s Cancer Institute in Kansas City, Missouri.
Speak to Author of the report @ https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-breast-cancer-liquid-biopsy-market
Major Market Competitors/Players: Global Breast Cancer Liquid Biopsy Market
Some of the major players operating in the global breast cancer liquid biopsy market are MDxHealth, QIAGEN, GUARDANT HEALTH, INC, Janssen Global Services, LLC, F. Hoffmann-La Roche Ltd, Menarini Silicon Biosystems., Thermo Fisher Scientific Inc, Biocept, Inc, Trovagene, Bio-Rad Laboratories, Inc., RainDance Technologies, Inc., Myriad Genetics, Inc, Fluxion Biosciences, Inc., Isogen Life Science B.V., Cynvenio Biosystems, Inc. Guardant Health, Inc., Biodesix, Inc, Genomic Health, FOUNDATION MEDICINE, INC, Sysmex Corporation, Exosome Diagnostics, NeoGenomics Laboratories, Inc. among others.
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research